Treatment of lung cancer: will financial issues become a criterion of choice?

References

• Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst. 103(2), 117–128 (2011).
   PubMed Web of Science ®Google Scholar
• Coate LE, Leighl NB. How affordable are targeted therapies in non-small cell lung cancer? Curr. Treat. Options Oncol. 12(1), 1–11 (2011).
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Leal J, Sullivan R. Economic burden of malignat neoplasms in the European Union. Ann. Oncol. 23(Suppl. 9), ixe25 (2012).
   Google Scholar
• Theriault RL. Health care costs: how do we decide value? When do we decide? How do we particularize the decisions? Oncologist 17(2), 157–159 (2012).
   Google Scholar
• Tsuchiya T, Fukuda T, Furuiye M, Kawabuchi K. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer 74(3), 521–528 (2011).
   Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase 3 study. Lancet 374(9699), 1432–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 30(1), 17–34 (2012).
   PubMed Web of Science ®Google Scholar
• Goulart B, Ramsey S. A trial-based assessment of the cost–utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14(6), 836–845 (2011).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 28(1), 75–92 (2010).
   Google Scholar
• Walleser S, Ray J, Bischoff H et al. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost–effectiveness in EGFR wild-type across Europe. Clinicoecon. Outcomes Res. 4, 269–275 (2012).
   PubMedGoogle Scholar
• Vergnenègre A, Ray JA, Chouaid C et al. Cross-market cost–effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon. Outcomes Res. 4, 31–37 (2012).
   PubMedGoogle Scholar
• Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 27(2), 113–125 (2009).
   PubMedGoogle Scholar
• Chouaid C, Monnet I, Robinet G, Perol M, Fournel P, Vergnenegre A. Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr. Med. Res. Opin. 23(7), 1509–1515 (2007).
   PubMed Web of Science ®Google Scholar
• Thongprasert S, Tinmanee S, Permsuwan U. Cost–utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. Asia. Pac. J. Clin. Oncol. 8(1), 53–61 (2012).
   PubMed Web of Science ®Google Scholar
• Horgan AM, Bradbury PA, Amir E et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann. Oncol. 22(8), 1805–1811 (2011).
   PubMed Web of Science ®Google Scholar
• Brown T, Boland A, Bagust A et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol. Assess. 14(Suppl. 2), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost–effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012).
   PubMed Web of Science ®Google Scholar
• Borget I, Cadranel J, Pignon JP et al.; ERMETIC Collaborative Group. Cost–effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur. Respir. J. 39(1), 172–179 (2012).
   PubMed Web of Science ®Google Scholar
• Chouaid C, Moser A, Coudray-Omnès C, Vergnenègre A. Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer. Rev. Mal. Respir. 25(9), 1096–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin. Transl. Oncol. 13(7), 460–471 (2011).
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Tu D, Seymour L et al.; NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl Cancer Inst. 102(5), 298–306 (2010).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61(3), 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis G, Peake M, Aultman R et al. Cost–effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J. Int. Med. Res. 38(1), 9–21 (2010).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR–tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20–27 (2009).
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Chien CR, Shih YC. Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). Clinicoecon. Outcomes Res. 4, 201–208 (2012).
   Google Scholar
• Giuliani G, Grossi F, de Marinis F, Walzer S. Cost–effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 69(Suppl. 1), S11–S17 (2010).
   Google Scholar
• Ahn MJ, Tsai CM, Hsia TC et al. Cost–effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. Asia. Pac. J. Clin. Oncol. 7(Suppl. 2), 22–33 (2011).
   PubMed Web of Science ®Google Scholar
• Mueller E. Editorial: comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer 69(Suppl. 1), S1–S3 (2010).
   Google Scholar
• Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 51(1), 115–121 (2006).
   PubMed Web of Science ®Google Scholar
• Raborn ML, Pelletier EM, Smith DB, Reyes CM. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US Claims Data Analysis. J. Oncol. Pract. 8(Suppl. 3), 9s–15s (2012).
   Google Scholar